Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18107886 | 0.75 | CA12 (0.37) | UCHL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL27186349 | 0.75 | NR4A2 (0.40) | KDM4EALDH1A1HPGDNPSR1NR4A2 | |
| SCHEMBL27186983 | 0.75 | KDM4E (0.38) | KDM4EALDH1A1HPGDNPSR1NR4A2 | |
| SCHEMBL20636622 | 0.74 | KDM4E (0.37) | UCHL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL9980580 | 0.73 | KDM4E (0.49) | UCHL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL17201303 | 0.73 | KDM4E (0.34) | UCHL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL27186402 | 0.73 | KLKB1 (0.31) | UCHL1 | |
| SCHEMBL3451361 | 0.71 | GAA (0.38) | UCHL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL17201350 | 0.71 | HTT (0.41) | UCHL1KDM4EHPGDPOLB | |
| SCHEMBL18120697 | 0.70 | UCHL1 (0.34) | UCHL1KDM4EALDH1A1HPGDHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| CN-117651701-A | Novel substituted bicyclic aza heterocycles as SOS1 inhibitors | 唯久生物技术(苏州)有限公司 | 2024-03-05 | — | — | CN | disclosed |
| WO-2022187266-A1 | NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109887-A1 | NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS | SOS1, SOS2, KSR1 | UCHL1 3505/4885KDM4E 1518/4885ALDH1A1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.